Get the Stockscreener App
725.72
4.21%
-31.88
Pre-market:
727.37
1.65
+0.23%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $725.72, with a volume of 5.39M.
It is down -4.21% in the last 24 hours and down -6.79% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$757.60
Open:
$747.83
24h Volume:
5.39M
Relative Volume:
1.44
Market Cap:
$689.73B
Revenue:
$40.86B
Net Income/Loss:
$8.37B
P/E Ratio:
78.46
EPS:
9.25
Net Cash Flow:
$-2.28B
1W Performance:
-9.27%
1M Performance:
-6.79%
6M Performance:
-19.86%
1Y Performance:
+15.39%
1-Day Range:
$725.01
$755.28
1-Week Range:
$725.01
$805.34
52-Week Range:
$612.70
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Is Eli Lilly And Co. (LLY) Splitting in the Near Future? - Yahoo Finance
Eli Lilly, Avago lead market cap stock movers on Monday - Investing.com
Eli Lilly and Company (NYSE:LLY) Trading Down 4.1%Here's What Happened - MarketBeat
Eli Lilly, Nvidia among Monday's market cap stock movers - Investing.com
Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.
Lilly, Merck team with Purdue University to pioneer new drug production methods - FiercePharma
Pediatric Medicines Market May See a Big Move | Eli Lilly, Johnson & Johnson, Pfizer - openPR
Jim Cramer Says ‘Eli Lilly and Company (LLY)’s Drug Is Superior In Terms Of Weight Reduction At The Same Dose’ - Yahoo Finance
Jim Cramer on Eli Lilly and Company (LLY)’s Q4 2024 Performance: ‘Aren’t As Strong As Wall Street Was Hoping’ - Insider Monkey
Should You Buy the Dip in Eli Lilly Stock Right Now? - MSN
Eli Lilly Faces a Dramatic Stock Plunge! Is This Your Chance to Cash In? - Jomfruland.net
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried? - sharewise
Here’s Why Jim Sees Eli Lilly and Company (LLY) as a Long-Term Buy - Insider Monkey
Why Is Cliff Asness Bullish On Eli Lilly and Company (LLY)? - Insider Monkey
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity? - The Motley Fool
Purdue, Lilly and Merck launch new manufacturing collaboration effort - Purdue Exponent
How Is The Market Feeling About Eli Lilly? - Benzinga
Leerink keeps Eli Lilly stock outperform on revenue growth - MSN
Meds made by Novo Nordisk, Pfizer, Eli Lilly among those up for Medicare price negotiations - Sherwood News
Leerink keeps Eli Lilly stock outperform on revenue growth By Investing.com - Investing.com Canada
Eli Lilly stock target cut, retains Buy rating on growth potential - MSN
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY) - StreetInsider.com
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Purdue aims to speed evolution of pharma manufacturing in collaboration with Lilly and Merck - Purdue University
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease - Yahoo Finance
Pace quickens at the Eli Lilly and Co. Lebanon site - Lebanon Reporter
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Burney Co. Has $24.47 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025? - The Motley Fool
FDA approves Lilly’s Omvoh for Crohn’s disease - WISH TV Indianapolis, IN
Eli Lilly & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Eli Lilly's Options: A Look at What the Big Money is Thinking - Benzinga
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today - Benzinga
Crohn’s Gets More Competitive As Lilly Lands Second Omvoh Okay - News & Insights
Lilly IBD biologic receives expanded US approval -January 16, 2025 at 11:01 am EST - Marketscreener.com
Lilly IBD biologic receives expanded US approval - European Pharmaceutical Review
Is Lilly Stock A Sell After Tumbling On Its Guidance Cut? - Investor's Business Daily
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson - BioPharma Dive
Eli Lilly and Co. employees donate food and money to The Caring Center - Lebanon Reporter
Founders Grove Wealth Partners LLC Acquires New Position in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Eli Lilly and Company (NYSE:LLY) Shares Acquired by Community Trust & Investment Co. - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Josh Gottheimer - MarketBeat
Rep. Josh Gottheimer Sells Eli Lilly and Company (NYSE:LLY) Stock - MarketBeat
US FDA approves expanded use of Lilly's bowel disease drug - Reuters
Today at JP Morgan: Spending Lilly’s billions, GSK’s Blenrep prepped, cautious optimism for China drug deals and a gene therapy breakout - FirstWord Pharma
Eli Lilly's SWOT analysis: stock poised for growth despite challenges - Investing.com
Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment - The Wall Street Journal
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease - Investors | Eli Lilly and Company
Stock Quote & Chart | Eli Lilly and Company - Investors | Eli Lilly and Company
Eli Lilly & Co. (LLY) Announces FDA Approval of Omvoh for Crohn's disease - StreetInsider.com
Eli Lilly is considering offering more Zepbound doses in vials at lower cost - STAT
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):